Emergent Biosolutions Inc (EBS) concluded trading on Thursday at a closing price of $6.36, with 4.72 million shares of worth about $30.0 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.48% during that period and on May 08, 2025 the price saw a gain of about 34.18%. Currently the company’s common shares owned by public are about 54.50M shares, out of which, 52.32M shares are available for trading.
Stock saw a price change of 29.27% in past 5 days and over the past one month there was a price change of 48.60%. Year-to-date (YTD), EBS shares are showing a performance of -33.47% which increased to 59.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.02 but also hit the highest price of $15.10 during that period. The average intraday trading volume for Emergent Biosolutions Inc shares is 1.24 million. The stock is currently trading 28.05% above its 20-day simple moving average (SMA20), while that difference is up 19.86% for SMA50 and it goes to -22.98% lower than SMA200.
Emergent Biosolutions Inc (NYSE: EBS) currently have 54.50M outstanding shares and institutions hold larger chunk of about 65.44% of that.
The stock has a current market capitalization of $345.59M and its 3Y-monthly beta is at 2.08. It has posted earnings per share of -$2.70 in the same period. It has Quick Ratio of 3.51 while making debt-to-equity ratio of 1.20. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EBS, volatility over the week remained 9.26% while standing at 7.90% over the month.
Stock’s fiscal year EPS is expected to rise by 410.87% while it is estimated to decrease by -284.62% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 30, 2024 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by Rodman & Renshaw stated Emergent Biosolutions Inc (EBS) stock as a Buy in their note to investors on August 22, 2024, suggesting a price target of $16 for the stock. Stock get a Hold rating from The Benchmark Company on August 29, 2023.
